Gravity Analytica

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

VTGN 11.01.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call

Full Press Release SEC Filings Our VTGN Tweets

About Gravity Analytica

Recent Filings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 1, 2024--Vistagen(NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast onThursday, November 7, 2024, at2:00 p.m. Pacific Time(5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter endedSeptember 30, 2024, and provide a corporate update.

Event:Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference CallDate:Thursday, November 7, 2024Time:2:00 p.m. Pacific Time(5:00 p.m. Eastern Time)US Dial-in (Toll-free):1-800-717-1738TOLL/International Dial-in:1-646-307-1865Conference ID:1196845Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1692083&tp_key=a59cae127b

An audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately5:00 p.m. Pacific Time(8:00 p.m. Eastern Time) onThursday, November 7, 2024. To listen to the replay, call toll-free 1-844-512-2921 withinthe United Statesor 1-412-317-6671 when calling internationally (toll). Please use the replay access ID number 1196845.

About Vistagen

Headquartered inSouth San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate olfactory system and brain neurocircuitry to achieve desired therapeutic benefits and differentiated safety without requiring systemic absorption or direct activity on neurons in the brain. Vistagen’s neuroscience pipeline also includes an oral prodrug, AV-101, with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241101158260/en/

Investors:Mark A. McPartlandVistagen Therapeuticsmarkmcp@vistagen.com

Media:Caren ScannellVistagen Therapeuticscscannell@vistagen.com

Source: Vistagen

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com